EC approves Roche’s lung cancer drug in combo Tx

Organisation: Position: Deadline Date: Location:

Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company is quoted in Reuters Health as saying.

The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).

NSCLC is the most common type of lung cancer, accounting for about 85% of all cases, Roche said.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.